Alpha 2.0
Login Register
» Authors » A E Warren

A E Warren

Explore the profile of A E Warren including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 121
Followers 0
Related Specialties
Pharmacy
Oncology
Cardiology & Vascular Diseases
Top 10 Co-Authors
I H Hall
C R Barnes
M Weiss
J T Gupton
C Gray
D A Gorman
S A Belanger
S Sanatani
B Miles
J R Wheaton
Published In
Arch Pharm (Weinheim)
Anticancer Res
Can J Cardiol
Clin EEG Neurosci
JAMA
Affiliations
Soon will be listed here.
Recent Articles
1.
Prominent Crista Terminalis in a Fetus
Evong Y, Warren A, Mohsin H
Images Paediatr Cardiol . 2019 Mar; 20(3):1-4. PMID: 30886637
Background: The crista terminalis is a normal cardiac structure located in the right atrium. It is not usually seen using standard view transthoracic echocardiography techniques, but on occasion, hypertrophy allows...
2.
Abstracts of Presentations at the International Conference on Basic and Clinical Multimodal Imaging (BaCI), a Joint Conference of the International Society for Neuroimaging in Psychiatry (ISNIP), the International Society for Functional Source...
He B, Nagata K, Takano D, Yamazaki T, Fujimaki Y, Maeda T, et al.
Clin EEG Neurosci . 2013 Dec; PMID: 24368763
No abstract available.
3.
Cardiac risk assessment before the use of stimulant medications in children and youth
Belanger S, Warren A, Hamilton R, Gray C, Gow R, Sanatani S, et al.
Paediatr Child Health . 2010 Nov; 14(9):579-92. PMID: 21037835
Regulatory decisions and scientific statements regarding the management of attention-deficit hyperactivity disorder (ADHD) raise questions about the safety of medications and the appropriate pretreatment evaluation to determine suitability for treatment...
4.
Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry
Warren A, Hamilton R, Belanger S, Gray C, Gow R, Sanatani S, et al.
Can J Cardiol . 2009 Nov; 25(11):625-30. PMID: 19898693
Regulatory decisions and scientific statements regarding the management of attention-deficit hyperactivity disorder (ADHD) raise questions about the safety of medications and the appropriate pretreatment evaluation to determine suitability for treatment...
5.
Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry
Hamilton R, Gray C, Belanger S, Warren A, Gow R, Sanatani S, et al.
J Can Acad Child Adolesc Psychiatry . 2009 Nov; 18(4):349-55. PMID: 19881947
No abstract available.
6.
Cytotoxicity of poly(phenolic)sulfonates and their sodium salts in l1210 lymphoid leukemia cells
Wang F, Warren A, Barnes C, Hall I
Met Based Drugs . 2008 May; 5(3):147-60. PMID: 18475836
Poly(phenolic)-sulfonates demonstrated very good cytotoxicity against the growth of tumor cell lines (L1210, Tmolt-(3), HeLa-S(3)) and are comparable in potency with typical clinically used anticancer drugs. Four of the most...
7.
Dilatation of the ascending aorta in paediatric patients with bicuspid aortic valve: frequency, rate of progression and risk factors
Warren A, Boyd M, OConnell C, Dodds L
Heart . 2006 Mar; 92(10):1496-500. PMID: 16547208
Objectives: To describe the incidence and rate of dilatation of the ascending aorta in children with bicuspid aortic valve (BAV) and to determine factors that predict rapid aortic dilatation. Design:...
8.
Targeting of human Tmolt4 leukemic type II IMP dehydrogenase by cyclic imide related derivatives
Hall I, Barnes B, Ward E, Wheaton J, Shaffer K, Cho S, et al.
Arch Pharm (Weinheim) . 2001 Aug; 334(7):229-34. PMID: 11512273
2,3-Dihydrophthalazine-1,4-diones, indazolones, 3-imino-1-oxoisodolines, homophthalimides, napthalidimides, diphenamides, and 6,7-dihydro-5H-dibenz[c,e]azepines proved to be potent inhibitors of the activity of human Tmolt4 T cell leukemia Type II IMP dehydrogenase (IMPDH). This inhibition was...
9.
Tmolt4 leukemic type II isoform of IMP dehydrogenase as a target for 1,2,4-triazolidine-3,5-diones, 1-(1-(3-methylphenyl)ethylidineamino)-4,4-diethyl-3,5-azetidinediones, 3,5-isoxazolidinediones, and 4,4-disubstituted-3,5-pyrazolidinediones
Hall I, Barnes B, Ward E, Wheaton J, Warren A, Izydore R
Arch Pharm (Weinheim) . 2001 May; 334(4):109-16. PMID: 11382145
The 1,2,4-triazolidine-3,5-diones, 1-(1-(3-methylphenyl)ethylidineamino)-4,4-diethyl-3,5-azetidinediones, and 4,4-disubstituted-3,5-pyrazolidinediones proved to be potent competitive inhibitors of human Tmolt4 leukemia Type II IMP dehydrogenase [IMPDH] activity, an enzyme isoform which is induced in highly proliferating...
10.
The cytotoxicity of 1-(1-phenylalkylideneamino)-2,4-azetidinediones and their mode of action in human and murine tumor cells
Izydore R, Zhang Y, Zhou X, Warren A, Wheaton J, Hall I
Anticancer Res . 2001 Apr; 21(1A):157-65. PMID: 11299729
The 1-(1-phenylalkylideneamino)-2,4-azetidinediones are potent cytotoxic agents against the growth of human and murine leukemias, lymphoma, and suspended HeLa uterine carcinoma. In cell lines cultured from solid human tumors, the agents...